Shandong Weigao Group Medical Polymer Company Limited (abbreviated “Weigao Group”) disclosed a further buyback of 0.46 million H-shares on 18 November 2026, executed on the Hong Kong Stock Exchange under its existing repurchase mandate approved on 29 May 2026.
• Transaction details: 460,000 shares were repurchased at prices between HKD 3.175 and HKD 3.26, translating into a volume-weighted average of HKD 3.2193 and an aggregate outlay of HKD 1.48 million.
• Capital structure impact: – Issued shares outstanding (excluding treasury shares) fell from 4.45176 billion to 4.45130 billion. – Treasury shares increased from 70.57 million to 71.03 million, now representing approximately 1.57 % of total issued shares of 4.52 billion. – The repurchase equates to 0.0103 % of Weigao Group’s pre-transaction share base.
• Mandate utilisation: The company is authorised to buy back up to 446.46 million shares. Cumulative purchases since the mandate’s adoption total 13.71 million shares, or 3.07 % of the share count in place on the mandate date.
• Holding status: All shares acquired on 18 November 2026 are held as treasury shares; none have been cancelled.
• Post-transaction restrictions: In line with Hong Kong listing rules, Weigao Group is subject to a moratorium on new share issues or treasury-share disposals until 19 December 2026.
The board confirms that the latest repurchase complied with all applicable regulatory requirements.
Comments